The 5 Most Hated Biotechs: Myriad, Sarepta, OncoMed, VIVUS, and MannKind
The five biotechs with the largest number of shares sold short as a percentage of float.
What You Ought To Know About Celgene's Deal-Making Magic
Celgene's investment team has made a string of savvy investments in early stage biotech companies.
5 States Where Pancreatic Cancer Prevalence Is the Highest
Pancreatic cancer has the lowest five-year survival rate and is the most prevalent in these five states. Here are the existing and developing therapies you need to have your eyes on.
This Week in Biotech: Clinical Trials and Tribulations
The J.P. Morgan Healthcare Conference led to the release of five important clinical updates this week.
Why OncoMed Pharmaceuticals, Inc. Shares Temporarily Spiked Higher
OncoMed Pharmaceuticals shares jump after the company releases early-stage data on two advanced pancreatic cancer drugs. Should investors be just as excited?
How Researchers Are Waging War on the Most Lethal Type of Cancer
Pancreatic cancer is the 12th most diagnosed cancer, but it is by far the most lethal. Find out how treatments are evolving and how patients and investors may soon benefit from these discoveries.
"Star Trek" Becomes Reality With These 3 Revolutionary Cancer-Fighting Methods
The next-generation of cancer-fighting agents could be right around the corner.
Is Celgene Really Overvalued?
High-profile analysts are worrying over Celgene's share price, but a strong pipeline suggests a bright future for the company.
Why LSI, AerCap Holdings, and OncoMed Pharmaceuticals Are Today's 3 Best Stocks
The S&P 500 puts its four-day losing streak in the rearview mirror following strong economic data, but LSI, AerCap, and OncoMed Pharmaceuticals stole the show with gains of more than 20%!
Novartis Strengthens in Oncology With Multiple Myeloma
Novartis' strong R&D proves itself in the face of rivals' acquisitions and restructuring